Antibodies to Complex Receptors

复合受体抗体

• 批准号: 6552158
• 负责人: SHARON H WILLIS
• 金额: $ 20.01万
• 依托单位: INTEGRAL MOLECULAR
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-01 至 2004-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6552158
• 关键词: HIV infections; biotechnology; chemokine; conformation; drug discovery /isolation; human immunodeficiency virus; immunologic substance development /preparation; lipid bilayer membrane; liposomes; monoclonal antibody; protein purification; receptor expression; virus receptors

DESCRIPTION (provided by applicant): ViraCore is a biotechnology company that is creating a drug discovery tool that is capable of presenting complex receptors in a nanometer-sized particle format. Specific ally, ViraCore is using "lipoparticles", nanometer -sized particles surrounded by a lipid bilayer and embedded with membrane-bound receptors, to purify and solubilize complex receptors from the cell surface while maintaining their structuraI integrity. The purpose of this proposal is to use lipoparticles to develop monoclonal antibodies directed to conformationally complex epitopes of membrane- bound receptors. Many of the receptors and epitopes that we will target are difficult or, in some cases, impossible to target using traditional methods, including activated receptor conformations and intracellular structures. Lipoparticles present a unique technology for the development of important new classes of antibodies and vaccine candidates. This proposal focuses principally on antibodies to chemokine receptors, a class of membrane-bound receptors involved in HIV infection, AIDS pathogenesis, and immunity. However, the results of this proposal can have a broad impact on the development of antibodies, vaccines, and therapeutics against a wide variety of complex receptors.

描述（由申请人提供）：ViraCore是一家生物技术公司，正在开发一种药物发现工具，能够以纳米尺寸的颗粒形式呈现复杂的受体。具体而言，ViraCore使用“脂质颗粒”（由脂质双层包围并包埋膜结合受体的纳米级颗粒）从细胞表面纯化和溶解复合受体，同时保持其结构完整性。该提议的目的是使用脂质颗粒来开发针对膜结合受体的构象复杂表位的单克隆抗体。我们将靶向的许多受体和表位很难或在某些情况下不可能使用传统方法靶向，包括活化的受体构象和细胞内结构。脂质体为开发重要的新型抗体和候选疫苗提供了独特的技术。该提案主要集中在趋化因子受体的抗体上，趋化因子受体是一类与HIV感染、AIDS发病机制和免疫有关的膜结合受体。然而，这一提议的结果可能对针对各种复杂受体的抗体、疫苗和治疗剂的开发产生广泛的影响。